Search results
Showing 1681 to 1695 of 2188 results for guidelines
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)
Discontinued Reference number: GID-MT516
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
NICE has developed a medtech innovation briefing (MIB) on the Neo Pedicle Screw System for spinal fusion surgery .
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
Agenda and papers of the NICE public board meeting on 17 July 2024
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
This guideline has been updated and replaced by NICE guideline NG92.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]